Researchers recently introduced a novel anti-TREM2 agonist antibody named 03O05. This therapeutic candidate shows significant potential for treating Alzheimer’s disease and multiple sclerosis. Unlike traditional antibodies that block receptor shedding, 03O05 preserves physiological processes. Therefore, it increases soluble TREM2 levels while activating neuroprotective microglial functions.

Triggering receptor expressed on myeloid cell-2 (TREM2) signaling is crucial for brain health. Specifically, it promotes the activity of disease-associated microglia. These cells clear toxic debris and maintain neuronal health. However, previous attempts to target this receptor often lowered soluble TREM2 levels. This reduction led to mixed clinical outcomes. Consequently, the team developed 03O05 as a ligand-mimetic solution.

Improving Brain Health with Anti-TREM2 Agonist Antibody

In the 5xFAD mouse model of Alzheimer’s, the treatment yielded impressive results. Chronic administration of the antibody promoted the clearance of filamentous amyloid-beta plaques. Furthermore, it reduced microgliosis while enhancing phagocytosis. These actions effectively ameliorated neuronal dystrophy. Additionally, the researchers observed elevated soluble TREM2 levels in both the serum and brain tissue.

The study also examined the impact on multiple sclerosis using a cuprizone model. During the recovery phase, 03O05 significantly enhanced microglial phagocytosis. This process successfully reduced degraded myelin basic protein. As a result, the antibody promoted remyelination and improved structural integrity. Because this approach does not induce neuroinflammation, it offers a safer therapeutic profile. In summary, shedding-permissive agonism represents a promising strategy for neurodegenerative diseases.

Frequently Asked Questions

How does the anti-TREM2 agonist antibody 03O05 differ from older versions?

Older agonist antibodies typically block the shedding of the TREM2 receptor. In contrast, 03O05 is shedding-permissive. This allows it to activate the receptor while increasing beneficial soluble TREM2 levels in the brain.

Does this antibody cause neuroinflammation?

No, the study findings indicate that 03O05 promotes a neuroprotective microglial phenotype. It achieves therapeutic effects without inducing harmful neuroinflammation in mouse models.

What are the primary benefits observed in Alzheimer's models?

The antibody helps clear amyloid-beta plaques and reduces damage to neurons. It also supports microglial health, which is essential for slowing the progression of Alzheimer’s disease.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always consult a qualified medical professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Chen B et al. A ligand-mimetic anti-TREM2 agonist antibody elevates soluble TREM2 and ameliorates pathology in mouse models of Alzheimer's disease and multiple sclerosis. J Neuroinflammation. 2026 Feb 23. doi: 10.1186/s12974-026-03733-2. PMID: 41731491.


2. Ulland TK, Colonna M. TREM2 — a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14(11):667-675.


3. Schlepckow K et al. Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease. Lancet Neurol. 2023 Nov;22(11):1048-1060.